Vaccines Unit Shines For GSK In 3Q

GlaxoSmithKline's vaccine's business, which has been under the spotlight this week following a US regulatory submission for its highly anticipated shingles vaccines, Shingrix, has come out shining in the third quarter – setting the stage for a strong full-year readout.